CEL-SCI Corporation announced the closing of a best-efforts offering on March 18, 2025. The offering consisted of 16,000,000 shares of its common stock, or pre-funded warrants in lieu thereof.
Total gross proceeds from the offering were approximately $2,560,000, before deducting placement agent fees and other offering expenses. The shares were sold at an offering price of $0.31 per share.
The company intends to use the net proceeds from this offering to fund the continued development of Multikine, for general corporate purposes, and for working capital. This capital is essential for advancing its clinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.